US OptionsDetailed Quotes
MSGE241220C22500
- 0.00
- 0.000.00%
15min DelayClose Dec 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover346.29%IV-34.54%PremiumDec 20, 2024Expiry Date11.87Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8992Delta0.0131Gamma2.72Leverage Ratio-0.2528Theta0.0023Rho2.44Eff Leverage0.0069Vega
Madison Square Garden Entertainment Stock Discussion
Sign in to post a comment
Here are Wednesday’s biggest calls on Wall Street:
RBC upgrades Estee Lauder $Estee Lauder (EL.US)$ to outperform from sector perform
RBC said it sees an attractive risk/reward.
“We are upgrading EL shares to Outperform. At this point, we believe EPS and investor sentiment have troughed and believe the risk-to-reward profile skews favorable.”
Morgan Stanley reiterates Tesla $Tesla (TSLA.US)$ as overweight
Morgan Sta...
RBC upgrades Estee Lauder $Estee Lauder (EL.US)$ to outperform from sector perform
RBC said it sees an attractive risk/reward.
“We are upgrading EL shares to Outperform. At this point, we believe EPS and investor sentiment have troughed and believe the risk-to-reward profile skews favorable.”
Morgan Stanley reiterates Tesla $Tesla (TSLA.US)$ as overweight
Morgan Sta...
8
1
1
The CEO's recent share selling, despite a director's significant insider purchase last year, may worry shareholders. Insiders owning a fair share of the company indicates alignment with common shareholders, but the absence of insider buying in the last three months could be concerning.
The lawsuit against Dolan could potentially impact the reputation and stock performance of Madison Square Garden Entertainment, Sphere Entertainment, and Madison Square Garden Sports. Dolan's attorney has dismissed the lawsuit as having 'absolutely no merit' and being an 'act of retaliation'.
Analysts worry about company's high P/S ratio and doubt a turnaround despite sturdy revenue performance. Elevated P/S hasn't yet affected stock price, but investors are recommended caution.
Pre-Market Stock Movers
Gapping up
$Fabrinet (FN.US)$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin (APP.US)$
...
Gapping up
$Fabrinet (FN.US)$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin (APP.US)$
...
22
1
1
Gainers
In reaction to earnings/guidance:
• $StoneCo (STNE.US)$ +28.4% (also announces executive hires), $On Holding (ONON.US)$ +8.27%, $Americas Gold And Silver (USAS.US)$ +3.85%, $Torrid (CURV.US)$ +0.8%
Other news:
• $Lexicon Pharmaceuticals (LXRX.US)$ +4.5% (enters into loan facility to support commercialization of sotagliflozin)
• $TMC the metals (TMC.US)$ +3.2% (signs term sheet for development of commercial system to collect deep-sea pol...
In reaction to earnings/guidance:
• $StoneCo (STNE.US)$ +28.4% (also announces executive hires), $On Holding (ONON.US)$ +8.27%, $Americas Gold And Silver (USAS.US)$ +3.85%, $Torrid (CURV.US)$ +0.8%
Other news:
• $Lexicon Pharmaceuticals (LXRX.US)$ +4.5% (enters into loan facility to support commercialization of sotagliflozin)
• $TMC the metals (TMC.US)$ +3.2% (signs term sheet for development of commercial system to collect deep-sea pol...
11
1
No comment yet
104247826 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")